Genetic approaches to facilitate antibacterial drug development

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 7, 2015, Pages

  Schnappinger, Dirk ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; CELL SCREENING; DRUG DEVELOPMENT; FATTY ACID SYNTHESIS; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENETICS; GROWTH INHIBITION; HUMAN; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; WHOLE CELL SCREENING; DRUG DESIGN; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DESIGN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84934779591     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021139     Document Type: Article

References (121)

1. Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE III, Sherman DR, Boshoff HI, Mizrahi V. 2012a. Pathway-selective sensitization of Mycobacterium tuber-culosis for target-based whole-cell screening. Chem Biol 19: 844-854.
2. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernandez R, Alemparte C, Remuinan MJ, Barros D, et al. 2012b. Identification of novel im-idazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PloS ONE 7: e52951.
3. Adams CP, Brantner VV. 2006. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25: 420-428.
4. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
5. Arnvig K, Young D. 2012. Non-coding RNA and its potential role in Mycobacterium tuberculosis pathogenesis. RNA Biol 9: 427-436.
6. Barelier S, Krimm I. 2011. Ligand specificity, privileged sub-structures and protein druggability from fragment-based screening. Curr Opin Chem Biol 15: 469-474.
7. Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spec-trum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
8. Bennani YL. 2012. Drug discovery in the next decade: In-novation needed ASAP. Drug Discov Today 17: S31-S44.
9. Blokpoel MC, Murphy HN, O’Toole R, Wiles S, Runn ES, Stewart GR, Young DB, Robertson BD. 2005. Tetracy-cline-inducible gene regulation in mycobacteria. Nucleic Acids Res 33: e22.
10. Boldrin F, Casonato S, Dainese E, Sala C, Dhar N, Palu G, Riccardi G, Cole ST, Manganelli R. 2010. Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res 38: e134.
11. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE III. 2004. The transcriptional responses of My-cobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J Biol Chem 279: 40174-40184.
12. Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S, et al. 2008. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 283: 19329-19341.
13. Brazas MD, Hancock RE. 2005. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today 10: 1245-1252.
14. Brotz-Oesterhelt H, Sass P. 2010. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 5: 1553-1579.
15. Brown AK, Taylor RC, Bhatt A, Futterer K, Besra GS. 2009. Platensimycin activity against mycobacterial b-ketoacyl-ACP synthases. PloS ONE 4: e6306.
16. Caceres NE, Harris NB, Wellehan JF, Feng Z, Kapur V, Bar-letta RG. 1997. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacteri-um smegmatis. J Bacteriol 179: 5046-5055.
17. Carroll P, Muttucumaru DG, Parish T. 2005. Use of a tetra-cycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegma-tis. Appl Environ Microbiol 71: 3077-3084.
18. Chakraborty S, Gruber T, Barry CE III, Boshoff HI, Rhee KY. 2013. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339: 88-91.
19. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, et al. 2009. High content screening identifies decaprenyl-phosphoribose 20 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5: e1000645.
20. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al. 2010. The genetic landscape of a cell. Science 327: 425-431.
21. Dartois V, Barry CE III. 2013. A medicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23: 4741-4750.
22. Davies J. 2006. Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 17: 287-290.
23. DeVito JA, Mills JA, Liu VG, Agarwal A, Sizemore CF, Yao Z, Stoughton DM, Cappiello MG, Barbosa MD, Foster LA, et al. 2002. An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol 20: 478-483.
24. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Nar-ayanasamy P, et al. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72: 85-97.
25. Dixon SJ, Costanzo M, Baryshnikova A, Andrews B, Boone C. 2009. Systematic mapping of genetic interaction networks. Annu Rev Genet 43: 601-625.
26. Donald RG, Skwish S, Forsyth RA, Anderson JW, Zhong T, Burns C, Lee S, Meng X, LoCastro L, Jarantow LW, et al. 2009. A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem Biol 16: 826-836.
27. Duckworth BP, Geders TW, Tiwari D, Boshoff HI, Sibbald PA, Barry CE III, Schnappinger D, Finzel BC, Aldrich CC. 2011. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem Biol 18: 1432-1441.
28. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, Riley LW, Schnappinger D. 2005. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repres-sor. Nucleic Acids Res 33: e21.
29. Fang F, Hoskins J, Butler JS. 2004. 5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 24: 10766-10776.
30. Fauman EB, Rai BK, Huang ES. 2011. Structure-based druggability assessment—Identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol 15: 463-468.
31. Feng Z, Barletta RG. 2003. Roles of Mycobacterium smegma-tis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 47: 283-291.
32. Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. Science 325: 1089-1093.
33. Freiberg C, Fischer HP, Brunner NA. 2005. Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants. Antimicrob Agents Chemother 49: 749-759.
34. Fu LM, Shinnick TM. 2007. Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide Gene-Chips. J Infect 54: 277-284.
35. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, Davis RW. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 21: 278-283.
36. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jar-amillo DF, Chu AM, Jordan MI, Arkin AP, Davis RW. 2004. Chemogenomic profiling: Identifying the func-tional interactions of small molecules in yeast. Proc Natl Acad Sci 101: 793-798.
37. Girgis HS, Hottes AK, Tavazoie S. 2009. Genetic architecture of intrinsic antibiotic susceptibility. PloS ONE 4: e5629.
38. Goude R, Amin AG, Chatterjee D, Parish T. 2009. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemo-ther 53: 4138-4146.
39. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM. 2012. Cholesterol catabolism by Mycobacterium tuberculosis requires transcrip-tional and metabolic adaptations. Chem Biol 19: 218-227.
40. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Kordulakova J, et al. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334-341.
41. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Rottger S, Altmann KH, Cole ST. 2012. Towards a new tuberculosis drug: Pyridomycin—Na-ture’s isoniazid. EMBO Mol Med 4: 1032-1042.
42. Hoskins J, Butler JS. 2008. RNA-based 5-fluorouracil toxic-ity requires the pseudouridylation activity of Cbf5p. Genetics 179: 323-330.
43. Hoskins J, Scott Butler J. 2007. Evidence for distinct DNA-and RNA-based mechanisms of 5-fluorouracil cytotoxicity in Saccharomyces cerevisiae. Yeast 24: 861-870.
44. Huber J, Donald RG, Lee SH, Jarantow LW, Salvatore MJ, Meng X, Painter R, Onishi RH, Occi J, Dorso K, et al. 2009. Chemical genetic identification of peptidogly-can inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem Biol 16: 837-848.
45. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, et al. 2000. Functional discovery via a compendium of expres-sion profiles. Cell 102: 109-126.
46. Ioerger TR, O’Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, et al. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PloS ONE 8: e75245.
47. Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Diez MT, Vicente F, Gonzalez I, Salazar O, et al. 2007. Isolation and structure of platencin: A FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angew Chem Int Ed Engl 46: 4684-4688.
48. Jiang B, Xu D, Allocco J, Parish C, Davison J, Veillette K, Sillaots S, Hu W, Rodriguez-Suarez R, Trosok S, et al. 2008. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem Biol 15: 363-374.
49. Kammler S, Lykke-Andersen S, Jensen TH. 2008. The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells. Mol Cancer Res 6: 990-995.
50. Karakousis PC, Williams EP, Bishai WR. 2008. Altered ex-pression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Che-mother 61: 323-331.
51. Kim JH, Wei JR, Wallach JB, Robbins RS, Rubin EJ, Schnappinger D. 2010. Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. Nucleic Acids Res 39: 2210-2220.
52. Kim JH, O’Brien KM, Sharma R, Boshoff HI, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC, et al. 2013. A genetic strategy to identify targets for the development of drugs that prevent bacte-rial persistence. Proc Natl Acad Sci 110: 19095-19100.
53. Klotzsche M, Ehrt S, Schnappinger D. 2009. Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res 37: 1778-1788.
54. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
55. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, et al. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3: 323-324.
56. Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, Hafsat S, Sherman DR, Wang MW. 2012. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PloS ONE 7: e39961.
57. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, et al. 2012. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324-331.
58. Lancini G, Pallanza R, Silvestri LG. 1969. Relationships be-tween bactericidal effect and inhibition of ribonucleic acid nucleotidyltransferase by rifampicin in Escherichia coli K-12. J Bacteriol 97: 761-768.
59. Larsen MH, Vilcheze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, et al. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Myco-bacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 46: 453-466.
60. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, Hwang SY, Brown PO, Davis RW. 1997. Yeast microarrays for genome wide parallel genetic and gene expres-sion analysis. Proc Natl Acad Sci 94: 13057-13062.
61. Leblanc C, Prudhomme T, Tabouret G, Ray A, Burbaud S, Cabantous S, Mourey L, Guilhot C, Chalut C. 2012. 40-Phosphopantetheinyl transferase PptT, a new drug tar-get required for Mycobacterium tuberculosis growth and persistence in vivo. PLoS Pathog 8: e1003097.
62. Lechartier B, Rybniker J, Zumla A, Cole ST. 2014. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 6: 158-168.
63. Lee W, St Onge RP, Proctor M, Flaherty P, Jordan MI, Arkin AP, Davis RW, Nislow C, Giaever G. 2005. Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet 1: e24.
64. Liang J, Zeng F, Guo A, Liu L, Guo N, Li L, Jin J, Wu X, Liu M, Zhao D, et al. 2011. Microarray analysis of the chelerythrine-induced transcriptome of Mycobacterium tuber-culosis. Curr Microbiol 62: 1200-1208.
65. Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, Tran K, Miller JH. 2010. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: Generating an antibiotic bar code. Antimicrob Agents Chemother 54: 1393-1403.
66. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, et al. 2004. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137.
67. Magnet S, Hartkoorn RC, Szekely R, Pato J, Triccas JA, Schneider P, Szantai-Kis C, Orfi L, Chambon M, Banfi D, et al. 2010. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90: 354-360.
68. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, et al. 2009. Benzothiazinones kill Mycobacterium tu-berculosis by blocking arabinan synthesis. Science 324: 801-804.
69. Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2: 215-218.
70. Mnaimneh S, Davierwala AP, Haynes J, Moffat J, Peng WT, Zhang W, Yang X, Pootoolal J, Chua G, Lopez A, et al. 2004. Exploration of essential gene functions via titrat-able promoter alleles. Cell 118: 31-44.
71. Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD. 2006. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60: 1109-1122.
72. Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Ger-stein M, Snyder M. 2008. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320: 1344-1349.
73. Olaleye O, Raghunand TR, Bhat S, He J, Tyagi S, Lamich-hane G, Gu P, Zhou J, Zhang Y, Grosset J, et al. 2010. Methionine aminopeptidases from Mycobacterium tuber-culosis as novel antimycobacterial targets. Chem Biol 17: 86-97.
74. Ollinger J, O’Malley T, Ahn J, Odingo J, Parish T. 2012. Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions. J Bacteriol 194: 2614-2619.
75. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C. 2004. Inte-gration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22: 62-69.
76. Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho CH, et al. 2006. Exploring the mode-of-action of bioactive com-pounds by chemical-genetic profiling in yeast. Cell 126: 611-625.
77. Pathania R, Zlitni S, Barker C, Das R, Gerritsma DA, Lebert J, Awuah E, Melacini G, Capretta FA, Brown ED. 2009. Chemical genomics in Escherichia coli identifies an inhib-itor of bacterial lipoprotein targeting. Nat Chem Biol 5: 849-856.
78. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. 2010. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9: 203-214.
79. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
80. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO. 2010. Druggable pockets and binding site cen-tric chemical space: A paradigm shift in drug discovery. Drug Discov Today 15: 656-667.
81. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculo-sis. Nat Med 19: 1157-1160.
82. Provvedi R, Boldrin F, Falciani F, Palu G, Manganelli R. 2009. Global transcriptional response to vancomycin in Mycobacterium tuberculosis. Microbiology 155: 1093-1102.
83. Remuinan MJ, Perez-Herran E, Rullas J, Alemparte C, Martinez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jimenez E, et al. 2013. Tetrahydropyrazolo[1,5-a]pyrim-idine-3-carboxamide and N-benzyl-60,70-dihydrospiro [piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PloS One 8: e60933.
84. Rengarajan J, Bloom BR, Rubin EJ. 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci 102: 8327-8332.
85. Rodriguez GM, Smith I. 2006. Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis. J Bacteriol 188: 424-430.
86. Rodriguez-Suarez R, Xu D, Veillette K, Davison J, Sillaots S, Kauffman S, Hu W, Bowman J, Martel N, Trosok S, et al. 2007. Mechanism-of-action determination of GMP syn-thase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem Biol 14: 1163-1175.
87. Roemer T, Boone C. 2013. Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol 9: 222-231.
88. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci 100: 12989-12994.
89. Sassetti CM, Boyd DH, Rubin EJ. 2001. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci 98: 12712-12717.
90. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagen-esis. Mol Microbiol 48: 77-84.
91. Schena M, Shalon D, Davis RW, Brown PO. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
92. Schnappinger D, Ehrt S. 2014. Regulated expression systems for mycobacteria and their applications. Microbiol Spectr 2: doi: 10.1128/microbiolspec.MGM1122-0018-2013.
93. Schweitzer BI, Dicker AP, Bertino JR. 1990. Dihydrofolate reductase as a therapeutic target. FASEB J 4: 2441-2452.
94. Scott DE, Coyne AG, Hudson SA, Abell C. 2012. Fragment based approaches in drug discovery and chemical biol-ogy. Biochemistry 51: 4990-5003.
95. Shi C, Geders TW, Park SW, Wilson DJ, Boshoff HI, Abayomi O, Barry CE III, Schnappinger D, Finzel BC, Aldrich CC. 2011. Mechanism-based inactivation by aro-matization of the transaminase BioA involved in biotin biosynthesis in Mycobacterium tuberculosis. J Am Chem Soc 133: 18194-18201.
96. Silver LL. 2011. Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109.
97. Slayden RA, Belisle JT. 2009. Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis. J Antimicrob Chemother 63: 451-457.
98. Smith AM, Ammar R, Nislow C, Giaever G. 2010. A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther 127: 156-164.
99. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, et al. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screen-ing. ACS Chem Biol 7: 1377-1384.
100. Stanley SA, Kawate T, Iwase N, Shimizu M, Clatworthy AE, Kazyanskaya E, Sacchettini JC, Ioerger TR, Siddiqi NA, Minami S, et al. 2013. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc Natl Acad Sci 110: 11565-11570.
101. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. 1977. Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci 74: 4767-4771.
102. Swinney DC, Anthony J. 2011. How were new medicines discovered? Nat Rev Drug Discov 10: 507-519.
103. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE III, et al. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809.
104. Tamae C, Liu A, Kim K, Sitz D, Hong J, Becket E, Bui A, Solaimani P, Tran KP, Yang H, et al. 2008. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol 190: 5981-5988.
105. Thorsing M, Klitgaard JK, Atilano ML, Skov MN, Kolmos HJ, Filipe SR, Kallipolitis BH. 2013. Thioridazine induces major changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus aure-us USA300. PloS ONE 8: e64518.
106. Usha V, Gurcha SS, Lovering AL, Lloyd AJ, Papaemmanouil A, Reynolds RC, Besra GS. 2011. Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against My-cobacterium tuberculosis. Microbiology 157: 290-299.
107. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, et al. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
108. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, et al. 2007. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci 104: 7612-7616.
109. Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, Ahmad I, Yang P, Zhang Y, Kim J, et al. 2013. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci 110: E2510-E2517.
110. Wecke T, Mascher T. 2011. Antibiotic research in the age of omics: From expression profiles to interspecies communication. J Antimicrob Chemother 66: 2689-2704.
111. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, Alber T, Sassetti CM, Rhee KY, Rubin EJ. 2011. Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci 108: 4176-4181.
112. Wilhelm BT, Marguerat S, Watt S, Schubert F, Wood V, Goodhead I, Penkett CJ, Rogers J, Bahler J. 2008. Dynam-ic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature 453: 1239-1243.
113. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. 1999. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci 96: 12833-12838.
114. Wilson R, Kumar P, Parashar V, Vilcheze C, Veyron-Churlet R, Freundlich JS, Barnes SW, Walker JR, Szymonifka MJ, Marchiano E, et al. 2013. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosyn-thesis. Nat Chem Biol 9: 499-506.
115. Woong Park S, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee K, Barry CE III, Aldrich CC, et al. 2011. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using reg-ulated gene expression. PLoS Pathog 7: e1002264.
116. Xu D, Sillaots S, Davison J, Hu W, Jiang B, Kauffman S, Martel N, Ocampo P, Oh C, Trosok S, et al. 2009. Chem-ical genetic profiling and characterization of small-mol-ecule compounds that affect the biosynthesis of unsatu-rated fatty acids in Candida albicans. J Biol Chem 284: 19754-19764.
117. Xu HH, Trawick JD, Haselbeck RJ, Forsyth RA, Yamamoto RT, Archer R, Patterson J, Allen M, Froelich JM, Taylor I, et al. 2010. Staphylococcus aureus TargetArray: Compre-hensive differential essential gene expression as a mech-anistic tool to profile antibacterials. Antimicrob Agents Chemother 54: 3659-3670.
118. Yin D, Fox B, Lonetto ML, Etherton MR, Payne DJ, Holmes DJ, Rosenberg M, Ji Y. 2004. Identification of antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics 5: 101-113.
119. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang CW, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, et al. 2006. Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother 50: 519-526.
120. Zhang YJ, Ioerger TR, Huttenhower C, Long JE, Sassetti CM, Sacchettini JC, Rubin EJ. 2012. Global assessment of genomic regions required for growth in Mycobacteri-um tuberculosis. PLoS Pathog 8: e1002946.
121. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, Wallis D, Galaviz S, Huttenhower C, et al. 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155: 1296-1308.